SEC Company Response from MEDICINOVA INC (MNOV) (CIK 0001226616) (MNOV) — Feb 8, 2021
MEDICINOVA INC (MNOV) (CIK 0001226616)
Date: Feb. 8, 2021 · CIK: 0001226616 · Accession: 0001193125-21-032125
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-252592
Letter
February 8, 2021
VIA EDGAR
Division of Corporation Finance
Office of Life Sciences
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Mr. Jeffrey Gabor
Re: Acceleration Request of MediciNova, Inc.
Registration Statement on Form S-3, filed January 29, 2021
(File No. 333-252592)
Ladies and Gentlemen:
Pursuant to Rules 460 and 461 under the Securities Act of 1933, as amended, MediciNova, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effectiveness of the above-referenced Registration Statement, to 4:00 p.m., Eastern Time, on Wednesday, February 10, 2021, or as soon thereafter as practicable.
Thank you for your assistance. If you should have any questions, please contact Jordan Murray of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, counsel to the Registrant, at (858) 436-8047.
Very truly yours,
/s/ Yuichi Iwaki
Show Raw Text
CORRESP 1 filename1.htm CORRESP February 8, 2021 VIA EDGAR Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. Jeffrey Gabor Re: Acceleration Request of MediciNova, Inc. Registration Statement on Form S-3, filed January 29, 2021 (File No. 333-252592) Ladies and Gentlemen: Pursuant to Rules 460 and 461 under the Securities Act of 1933, as amended, MediciNova, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effectiveness of the above-referenced Registration Statement, to 4:00 p.m., Eastern Time, on Wednesday, February 10, 2021, or as soon thereafter as practicable. Thank you for your assistance. If you should have any questions, please contact Jordan Murray of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, counsel to the Registrant, at (858) 436-8047. Very truly yours, /s/ Yuichi Iwaki Yuichi Iwaki President and Chief Executive Officer